In addition, some studies have reported the possibility that HMGA2 is involved in modulating the resistance mechanism of other anti-nasopharyngeal cancer drugs, such as docetaxel, and resistance to targeted therapy drugs. Here, HMGA2 is linked to nasopharyngeal carcinoma.